Trial Profile
Phase II Study of Hyper-CVAD Plus Imatinib Mesylate (Gleevec, STI571) for Philadelphia-Positive Acute Lymphocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 May 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Granulocyte colony-stimulating factors; Mesna; Methotrexate; Methotrexate; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 19 May 2023 Results evaluating its efficacy ponatinib versus imatinib-based regimens using a matching adjusted indirect comparison from NCT00038610 , NCT00327678, NCT01424982 and NCT01641107; published in the Advances in Therapy
- 09 Nov 2022 Results of a matched adjusting Indirect comparison in two studies (GRAAPH-2005 and NCT00038610) assessing efficacy of ponatinib as frontline treatment in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia were presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 01 Apr 2021 Results assessing the prognostic factors for progression and survival and to the role of ASCT in patients who achieve a CMR within 3 months of therapy using data from NCT00038610, NCT00390793, and NCT01424982 published in the Cancer.